These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 26051505)

  • 1. Disease burden of chronic hepatitis C in Brazil.
    Ferreira PR; Brandão-Mello CE; Estes C; Gonçales Júnior FL; Coelho HS; Razavi H; Cheinquer H; Wolff FH; Ferraz ML; Pessoa MG; Mendes-Correa MC
    Braz J Infect Dis; 2015; 19(4):363-8. PubMed ID: 26051505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forecasting the disease burden of chronic hepatitis C virus in Poland.
    Flisiak R; Halota W; Tomasiewicz K; Kostrzewska K; Razavi HA; Gower EE
    Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):70-6. PubMed ID: 25426979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.
    Cramp ME; Rosenberg WM; Ryder SD; Blach S; Parkes J
    BMC Gastroenterol; 2014 Aug; 14():137. PubMed ID: 25100159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
    Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
    Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimates on HCV disease burden worldwide - filling the gaps.
    Wedemeyer H; Dore GJ; Ward JW
    J Viral Hepat; 2015 Jan; 22 Suppl 1():1-5. PubMed ID: 25560838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.
    Allaire M; Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; DI Martino V; Sutton A; Letouzé E; Audureau E; Roudot-Thoraval F;
    Hepatology; 2018 Oct; 68(4):1245-1259. PubMed ID: 29663511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic hepatitis C in the Czech Republic: Forecasting the disease burden.
    Fraňková S; Urbánek P; Husa P; Němeček V; Razavi H; Razavi-Shearer D; Chlíbek R; Šperl J
    Cent Eur J Public Health; 2019 Jun; 27(2):93-98. PubMed ID: 31241282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burden of disease and cost of chronic hepatitis C infection in Canada.
    Myers RP; Krajden M; Bilodeau M; Kaita K; Marotta P; Peltekian K; Ramji A; Estes C; Razavi H; Sherman M
    Can J Gastroenterol Hepatol; 2014 May; 28(5):243-50. PubMed ID: 24839620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift.
    Aljumah AA; Abaalkhail F; Al-Ashgar H; Assiri A; Babatin M; Al Faleh F; Alghamdi A; Al-Hakeem R; Hashim A; Alqutub A; Razavi H; Sanai FM; Al-Swat K; Schmelzer J; Altraif I
    Saudi J Gastroenterol; 2016; 22(4):269-81. PubMed ID: 27488321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The burden of hepatitis C in England.
    Sweeting MJ; De Angelis D; Brant LJ; Harris HE; Mann AG; Ramsay ME
    J Viral Hepat; 2007 Aug; 14(8):570-6. PubMed ID: 17650291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis.
    Cheinquer N; Cheinquer H; Wolff FH; Coelho-Borges S
    Braz J Infect Dis; 2010; 14(5):457-61. PubMed ID: 21221473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural History of Hepatitis C.
    Lingala S; Ghany MG
    Gastroenterol Clin North Am; 2015 Dec; 44(4):717-34. PubMed ID: 26600216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile and value of FIB-4 in patients with dual chronic hepatitis C and B.
    Liu CJ; Tseng TC; Yang WT; Su TH; Yang HC; Liu CH; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2019 Feb; 34(2):410-417. PubMed ID: 30151861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C and hepatitis B-related mortality in Spain.
    García-Fulgueiras A; García-Pina R; Morant C; García-Ortuzar V; Génova R; Alvarez E
    Eur J Gastroenterol Hepatol; 2009 Aug; 21(8):895-901. PubMed ID: 19357523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway.
    Kileng H; Bernfort L; Gutteberg T; Moen OS; Kristiansen MG; Paulssen EJ; Berg LK; Florholmen J; Goll R
    BMC Infect Dis; 2017 Sep; 17(1):624. PubMed ID: 28915795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
    Moon C; Jung KS; Kim DY; Baatarkhuu O; Park JY; Kim BK; Kim SU; Ahn SH; Han KH
    Dig Dis Sci; 2015 Feb; 60(2):573-81. PubMed ID: 25236421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.